![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: DACT1 |
Gene summary for DACT1 |
![]() |
Gene information | Species | Human | Gene symbol | DACT1 | Gene ID | 51339 |
Gene name | dishevelled binding antagonist of beta catenin 1 | |
Gene Alias | DAPPER | |
Cytomap | 14q23.1 | |
Gene Type | protein-coding | GO ID | GO:0000082 | UniProtAcc | Q9NYF0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51339 | DACT1 | S014 | Human | Liver | HCC | 5.15e-16 | 9.18e-01 | 0.2254 |
51339 | DACT1 | S015 | Human | Liver | HCC | 3.20e-05 | 6.49e-01 | 0.2375 |
51339 | DACT1 | S016 | Human | Liver | HCC | 4.45e-15 | 8.79e-01 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000989622 | Liver | HCC | positive regulation of catabolic process | 335/7958 | 492/18723 | 3.83e-31 | 1.87e-28 | 335 |
GO:003133122 | Liver | HCC | positive regulation of cellular catabolic process | 295/7958 | 427/18723 | 3.20e-29 | 1.45e-26 | 295 |
GO:004217622 | Liver | HCC | regulation of protein catabolic process | 267/7958 | 391/18723 | 2.45e-25 | 7.38e-23 | 267 |
GO:003164722 | Liver | HCC | regulation of protein stability | 211/7958 | 298/18723 | 2.29e-23 | 5.01e-21 | 211 |
GO:190336222 | Liver | HCC | regulation of cellular protein catabolic process | 182/7958 | 255/18723 | 5.91e-21 | 8.52e-19 | 182 |
GO:004573222 | Liver | HCC | positive regulation of protein catabolic process | 163/7958 | 231/18723 | 4.00e-18 | 4.69e-16 | 163 |
GO:004325422 | Liver | HCC | regulation of protein-containing complex assembly | 264/7958 | 428/18723 | 5.47e-16 | 4.39e-14 | 264 |
GO:190336422 | Liver | HCC | positive regulation of cellular protein catabolic process | 115/7958 | 155/18723 | 9.30e-16 | 7.19e-14 | 115 |
GO:005109822 | Liver | HCC | regulation of binding | 225/7958 | 363/18723 | 3.78e-14 | 2.37e-12 | 225 |
GO:004339322 | Liver | HCC | regulation of protein binding | 129/7958 | 196/18723 | 3.27e-11 | 1.26e-09 | 129 |
GO:00447722 | Liver | HCC | mitotic cell cycle phase transition | 240/7958 | 424/18723 | 2.47e-09 | 6.84e-08 | 240 |
GO:000734611 | Liver | HCC | regulation of mitotic cell cycle | 255/7958 | 457/18723 | 4.96e-09 | 1.30e-07 | 255 |
GO:019873821 | Liver | HCC | cell-cell signaling by wnt | 247/7958 | 446/18723 | 2.11e-08 | 4.96e-07 | 247 |
GO:001605521 | Liver | HCC | Wnt signaling pathway | 245/7958 | 444/18723 | 3.68e-08 | 8.09e-07 | 245 |
GO:005109922 | Liver | HCC | positive regulation of binding | 108/7958 | 173/18723 | 9.22e-08 | 1.83e-06 | 108 |
GO:003133312 | Liver | HCC | negative regulation of protein-containing complex assembly | 91/7958 | 141/18723 | 1.01e-07 | 1.98e-06 | 91 |
GO:003209221 | Liver | HCC | positive regulation of protein binding | 59/7958 | 85/18723 | 4.66e-07 | 7.61e-06 | 59 |
GO:19019901 | Liver | HCC | regulation of mitotic cell cycle phase transition | 167/7958 | 299/18723 | 1.96e-06 | 2.71e-05 | 167 |
GO:19019871 | Liver | HCC | regulation of cell cycle phase transition | 211/7958 | 390/18723 | 2.11e-06 | 2.89e-05 | 211 |
GO:003011121 | Liver | HCC | regulation of Wnt signaling pathway | 180/7958 | 328/18723 | 3.62e-06 | 4.72e-05 | 180 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DACT1 | SNV | Missense_Mutation | novel | c.2153C>T | p.Ala718Val | p.A718V | Q9NYF0 | protein_coding | deleterious(0) | benign(0.314) | TCGA-EY-A1GU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DACT1 | SNV | Missense_Mutation | novel | c.1859N>T | p.Thr620Ile | p.T620I | Q9NYF0 | protein_coding | tolerated(0.11) | possibly_damaging(0.859) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
DACT1 | SNV | Missense_Mutation | rs369586925 | c.2476N>T | p.Arg826Trp | p.R826W | Q9NYF0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
DACT1 | SNV | Missense_Mutation | rs776288208 | c.1089N>G | p.Asn363Lys | p.N363K | Q9NYF0 | protein_coding | deleterious(0.02) | possibly_damaging(0.69) | TCGA-DD-A11D-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Targeted Molecular therapy | sorafenib | PD |
DACT1 | SNV | Missense_Mutation | novel | c.805N>C | p.Tyr269His | p.Y269H | Q9NYF0 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-DD-AACU-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
DACT1 | SNV | Missense_Mutation | c.1256N>T | p.Trp419Leu | p.W419L | Q9NYF0 | protein_coding | tolerated(0.6) | benign(0.086) | TCGA-ED-A7PZ-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
DACT1 | SNV | Missense_Mutation | novel | c.1492N>A | p.Gln498Lys | p.Q498K | Q9NYF0 | protein_coding | tolerated(1) | benign(0) | TCGA-05-4427-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
DACT1 | SNV | Missense_Mutation | novel | c.2396N>A | p.Pro799Gln | p.P799Q | Q9NYF0 | protein_coding | tolerated(0.14) | benign(0.022) | TCGA-05-4427-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
DACT1 | SNV | Missense_Mutation | c.1062N>T | p.Arg354Ser | p.R354S | Q9NYF0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-44-2657-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
DACT1 | SNV | Missense_Mutation | novel | c.253N>T | p.Arg85Cys | p.R85C | Q9NYF0 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-49-6742-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | alimta | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |